查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1962139

全球数位生物标记市场规模、份额、趋势和成长分析报告（2026-2034）

Global Digital Biomarkers Market Size, Share, Trends & Growth Analysis Report 2026-2034
出版日期: | 出版商: Value Market Research | 英文 178 Pages | 商品交期: 最快1-2个工作天内

价格
简介目录

数位生物标记市场预计将从 2025 年的 58.3 亿美元成长到 2034 年的 372.9 亿美元，2026 年至 2034 年的复合年增长率为 22.91%。

在技​​术进步的推动下，数位生物标记市场正迅速扩张，这些进步催生了用于健康监测和疾病管理的创新解决方案。数位生物标记是指透过数位设备收集的客观、可量化的生理和行为数据，它正在改变医疗服务提供者评估患者健康状况和治疗效果的方式。透过利用穿戴式装置、行动应用程式和远端监测工具，医疗专业人员可以即时了解患者​​的病情，从而提供更个人化和主动的护理。

此外，将人工智慧 (AI) 和机器学习技术融入数位生物标记分析，正在提升这些工具的准确性和预测能力。人工智慧演算法能够分析大量数据，识别传统方法无法发现的模式和关联性，从而实现更早发现健康问题并采取更有效的干预措施。这种向数据驱动型医疗保健的转变，赋予了患者在自身健康管理中更积极主动的角色，并促进了他们参与治疗方案并坚持治疗。

此外，人们对预防医学和慢性病管理的日益关注也推动了对数位生物标记的需求。随着全球医疗系统努力降低成本并改善治疗效果，远端、持续监测健康指标的能力变得愈发重要。数位生物标记有助于及时干预、减少住院次数并提高患者的整体生活品质。

目录

第一章：引言

第二章执行摘要

第三章 市场变数、趋势与框架

  • 市场谱系展望
  • 渗透率和成长前景分析
  • 价值链分析
  • 法律规范
    • 标准与合规性
    • 监管影响分析
  • 市场动态
    • 市场驱动因素
    • 市场限制因素
    • 市场机会
    • 市场挑战
  • 波特五力分析
  • PESTLE分析

第四章：全球数位生物标记市场：按类型划分

  • 市场分析、洞察与预测
  • 穿戴式装置
  • 基于行动装置的应用程式
  • 感应器
  • 其他的

第五章 全球数位生物标记市场：依临床实务划分

  • 市场分析、洞察与预测
  • 用于诊断的数位生物标记
  • 数位生物标记的监测
  • 预测性和预后性数位生物标记物
  • 其他的

第六章 全球数位生物标记市场：依治疗领域划分

  • 市场分析、洞察与预测
  • 心血管和代谢疾病（CVMD）
  • 呼吸系统疾病
  • 精神疾病
  • 睡眠/运动障碍
  • 神经系统疾病
  • 肌肉骨骼疾病
  • 其他的

第七章 全球数位生物标记市场：依最终用途划分

  • 市场分析、洞察与预测
  • 医疗保健公司
  • 医疗服务提供方
  • 付款人
  • 其他的

第八章 全球数位生物标记市场：按地区划分

  • 区域分析
  • 北美市场分析、洞察与预测
    • 我们
    • 加拿大
    • 墨西哥
  • 欧洲市场分析、洞察与预测
    • 英国
    • 法国
    • 德国
    • 义大利
    • 俄罗斯
    • 其他欧洲国家
  • 亚太市场分析、洞察与预测
    • 印度
    • 日本
    • 韩国
    • 澳洲
    • 东南亚
    • 其他亚太国家
  • 拉丁美洲市场分析、洞察与预测
    • 巴西
    • 阿根廷
    • 秘鲁
    • 智利
    • 其他拉丁美洲国家
  • 中东和非洲市场分析、洞察与预测
    • 沙乌地阿拉伯
    • UAE
    • 以色列
    • 南非
    • 其他中东和非洲国家

第九章 竞争情势

  • 最新趋势
  • 公司分类
  • 供应链和销售管道合作伙伴（根据现有资讯）
  • 市场占有率和市场定位分析（基于现有资讯）
  • 供应商情况（基于现有资讯）
  • 策略规划

第十章：公司简介

  • 主要公司的市占率分析
  • 公司简介
    • Amgen Inc
    • Biogen Inc
    • ActiGraph LLC
    • AliveCor Inc
    • Empatica Inc
    • IXICO Plc
    • Neurotrack Technologies Inc
    • Clario
    • Koneksa
    • Huma
    • Sonde Health Inc
    • Aural Analytics
    • Adherium Limited
    • Imagene AI
    • Brainomix
简介目录
Product Code: VMR112111961

The Digital Biomarkers Market size is expected to reach USD 37.29 Billion in 2034 from USD 5.83 Billion (2025) growing at a CAGR of 22.91% during 2026-2034.

The Digital Biomarkers Market is rapidly expanding as advancements in technology enable the development of innovative solutions for health monitoring and disease management. Digital biomarkers, which are objective, quantifiable physiological and behavioral data collected through digital devices, are transforming how healthcare providers assess patient health and treatment efficacy. By leveraging wearables, mobile applications, and remote monitoring tools, healthcare professionals can gain real-time insights into patient conditions, leading to more personalized and proactive care.

Moreover, the integration of artificial intelligence and machine learning into digital biomarker analysis is enhancing the accuracy and predictive capabilities of these tools. AI algorithms can analyze vast amounts of data to identify patterns and correlations that may not be apparent through traditional methods, enabling earlier detection of health issues and more effective interventions. This shift towards data-driven healthcare is empowering patients to take an active role in managing their health, fostering greater engagement and adherence to treatment plans.

Additionally, the growing emphasis on preventive healthcare and chronic disease management is driving demand for digital biomarkers. As healthcare systems worldwide seek to reduce costs and improve outcomes, the ability to monitor health metrics remotely and continuously is becoming increasingly valuable. Digital biomarkers can facilitate timely interventions, reduce hospitalizations, and enhance overall patient quality of life.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Type

  • Wearable
  • Mobile Based Applications
  • Sensors
  • Others

By Clinical Practice

  • Diagnostic Digital Biomarkers
  • Monitoring Digital Biomarkers
  • Predictive And Prognostic Digital Biomarkers
  • Others

By Therapeutic Area

  • Cardiovascular And Metabolic Disorders (CVMD)
  • Respiratory Disorders
  • Psychiatric Disorders
  • Sleep & Movement Disease
  • Neurological Disorders
  • Musculoskeletal Disorders
  • Others

By End-Use Outlook

  • Healthcare Companies
  • Healthcare Providers
  • Payers
  • Others

COMPANIES PROFILED

  • Amgen Inc, Biogen Inc, ActiGraph LLC, AliveCor Inc, Empatica Inc, IXICO plc, Neurotrack Technologies Inc, Clario, Koneksa, Huma, Sonde Health Inc, Aural Analytics, Adherium Limited, Imagene AI, Brainomix

We can customise the report as per your requriements

TABLE OF CONTENTS

Chapter 1. PREFACE

  • 1.1. Market Segmentation & Scope
  • 1.2. Market Definition
  • 1.3. Information Procurement
    • 1.3.1 Information Analysis
    • 1.3.2 Market Formulation & Data Visualization
    • 1.3.3 Data Validation & Publishing
  • 1.4. Research Scope and Assumptions
    • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

  • 2.1. Market Snapshot
  • 2.2. Segmental Outlook
  • 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

  • 3.1. Market Lineage Outlook
  • 3.2. Penetration & Growth Prospect Mapping
  • 3.3. Value Chain Analysis
  • 3.4. Regulatory Framework
    • 3.4.1 Standards & Compliance
    • 3.4.2 Regulatory Impact Analysis
  • 3.5. Market Dynamics
    • 3.5.1 Market Drivers
    • 3.5.2 Market Restraints
    • 3.5.3 Market Opportunities
    • 3.5.4 Market Challenges
  • 3.6. Porter's Five Forces Analysis
  • 3.7. PESTLE Analysis

Chapter 4. GLOBAL DIGITAL BIOMARKERS MARKET: BY TYPE 2022-2034 (USD MN)

  • 4.1. Market Analysis, Insights and Forecast Type
  • 4.2. Wearable Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.3. Mobile Based Applications Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.4. Sensors Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.5. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL DIGITAL BIOMARKERS MARKET: BY CLINICAL PRACTICE 2022-2034 (USD MN)

  • 5.1. Market Analysis, Insights and Forecast Clinical Practice
  • 5.2. Diagnostic Digital Biomarkers Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.3. Monitoring Digital Biomarkers Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.4. Predictive And Prognostic Digital Biomarkers Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.5. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL DIGITAL BIOMARKERS MARKET: BY THERAPEUTIC AREA 2022-2034 (USD MN)

  • 6.1. Market Analysis, Insights and Forecast Therapeutic Area
  • 6.2. Cardiovascular And Metabolic Disorders (CVMD) Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 6.3. Respiratory Disorders Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 6.4. Psychiatric Disorders Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 6.5. Sleep & Movement Disease Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 6.6. Neurological Disorders Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 6.7. Musculoskeletal Disorders Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 6.8. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL DIGITAL BIOMARKERS MARKET: BY END-USE OUTLOOK 2022-2034 (USD MN)

  • 7.1. Market Analysis, Insights and Forecast End-use Outlook
  • 7.2. Healthcare Companies Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 7.3. Healthcare Providers Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 7.4. Payers Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 7.5. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 8. GLOBAL DIGITAL BIOMARKERS MARKET: BY REGION 2022-2034(USD MN)

  • 8.1. Regional Outlook
  • 8.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 8.2.1 By Type
    • 8.2.2 By Clinical Practice
    • 8.2.3 By Therapeutic Area
    • 8.2.4 By End-use Outlook
    • 8.2.5 United States
    • 8.2.6 Canada
    • 8.2.7 Mexico
  • 8.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 8.3.1 By Type
    • 8.3.2 By Clinical Practice
    • 8.3.3 By Therapeutic Area
    • 8.3.4 By End-use Outlook
    • 8.3.5 United Kingdom
    • 8.3.6 France
    • 8.3.7 Germany
    • 8.3.8 Italy
    • 8.3.9 Russia
    • 8.3.10 Rest Of Europe
  • 8.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 8.4.1 By Type
    • 8.4.2 By Clinical Practice
    • 8.4.3 By Therapeutic Area
    • 8.4.4 By End-use Outlook
    • 8.4.5 India
    • 8.4.6 Japan
    • 8.4.7 South Korea
    • 8.4.8 Australia
    • 8.4.9 South East Asia
    • 8.4.10 Rest Of Asia Pacific
  • 8.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 8.5.1 By Type
    • 8.5.2 By Clinical Practice
    • 8.5.3 By Therapeutic Area
    • 8.5.4 By End-use Outlook
    • 8.5.5 Brazil
    • 8.5.6 Argentina
    • 8.5.7 Peru
    • 8.5.8 Chile
    • 8.5.9 South East Asia
    • 8.5.10 Rest of Latin America
  • 8.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 8.6.1 By Type
    • 8.6.2 By Clinical Practice
    • 8.6.3 By Therapeutic Area
    • 8.6.4 By End-use Outlook
    • 8.6.5 Saudi Arabia
    • 8.6.6 UAE
    • 8.6.7 Israel
    • 8.6.8 South Africa
    • 8.6.9 Rest of the Middle East And Africa

Chapter 9. COMPETITIVE LANDSCAPE

  • 9.1. Recent Developments
  • 9.2. Company Categorization
  • 9.3. Supply Chain & Channel Partners (based on availability)
  • 9.4. Market Share & Positioning Analysis (based on availability)
  • 9.5. Vendor Landscape (based on availability)
  • 9.6. Strategy Mapping

Chapter 10. COMPANY PROFILES OF GLOBAL DIGITAL BIOMARKERS INDUSTRY

  • 10.1. Top Companies Market Share Analysis
  • 10.2. Company Profiles
    • 10.2.1 Amgen Inc
    • 10.2.2 Biogen Inc
    • 10.2.3 ActiGraph LLC
    • 10.2.4 AliveCor Inc
    • 10.2.5 Empatica Inc
    • 10.2.6 IXICO Plc
    • 10.2.7 Neurotrack Technologies Inc
    • 10.2.8 Clario
    • 10.2.9 Koneksa
    • 10.2.10 Huma
    • 10.2.11 Sonde Health Inc
    • 10.2.12 Aural Analytics
    • 10.2.13 Adherium Limited
    • 10.2.14 Imagene AI
    • 10.2.15 Brainomix